Currently, different biomarkers have been investigated with variable success in the selection of patients eligible for cancer immunotherapy, such as FDA-approved PD-L1 expression, microsatellite instability-high and/or mismatch repair status, and tumor mutation burden (TMB) (13–15). This evidence concerns the gene CD274 and cancer.